- Stocks
- Healthcare
- NYSE: HAE

Price (delayed)

$60.07

Market cap

$3.06B

P/E Ratio

38.26

Dividend/share

N/A

EPS

$1.57

Enterprise value

$3.58B

The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 162.3 and 29% lower than the last 4 quarters average of 53.7

The equity is up by 25% year-on-year

The company's quick ratio fell by 27% QoQ but it rose by 15% YoY

The company's EPS fell by 27% QoQ but it rose by 4% YoY

The debt has soared by 128% since the previous quarter and by 85% year-on-year

The company's gross profit fell by 18% YoY and by 7% QoQ

What are the main financial stats of HAE

Market
Valuations
Earnings

Shares outstanding

50.95M

Market cap

$3.06B

Enterprise value

$3.58B

Price to earnings (P/E)

38.26

Price to book (P/B)

4.17

Price to sales (P/S)

3.5

EV/EBIT

39.85

EV/EBITDA

20.55

EV/Sales

4.11

Revenue

$870.46M

EBIT

$89.75M

EBITDA

$174.03M

Free cash flow

$73.58M

Per share
Balance sheet
Liquidity

EPS

$1.57

Free cash flow per share

$1.45

Book value per share

$14.4

Revenue per share

$17.17

TBVPS

$19.49

Total assets

$1.82B

Total liabilities

$1.09B

Debt

$707.61M

Equity

$731.67M

Working capital

$440.05M

Debt to equity

0.97

Current ratio

2.74

Quick ratio

1.26

Net debt/EBITDA

2.96

Margins
Efficiency
Dividend

EBITDA margin

20%

Gross margin

45.7%

Net margin

9.1%

Operating margin

10.3%

Return on assets

5.3%

Return on equity

11.7%

Return on invested capital

9%

Return on capital employed

5.7%

Return on sales

10.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Haemonetics stock price performed over time

Intraday

2.84%

1 week

9.06%

1 month

0.67%

1 year

-32.67%

YTD

-49.41%

QTD

-45.89%

How have Haemonetics's revenue and profit performed over time

Revenue

$870.46M

Gross profit

$397.84M

Operating income

$89.75M

Net income

$79.47M

Gross margin

45.7%

Net margin

9.1%

The operating income is down by 34% since the previous quarter and by 13% year-on-year

The operating margin has contracted by 34% from the previous quarter

HAE's net income is down by 27% since the previous quarter but it is up by 3.8% year-on-year

The net margin is down by 25% since the previous quarter but it is up by 18% year-on-year

What is Haemonetics's growth rate over time

What is Haemonetics stock price valuation

P/E

38.26

P/B

4.17

P/S

3.5

EV/EBIT

39.85

EV/EBITDA

20.55

EV/Sales

4.11

The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 162.3 and 29% lower than the last 4 quarters average of 53.7

The company's EPS fell by 27% QoQ but it rose by 4% YoY

The price to book (P/B) is 44% lower than the last 4 quarters average of 7.5 and 33% lower than the 5-year quarterly average of 6.2

The equity is up by 25% year-on-year

The stock's P/S is 39% less than its last 4 quarters average of 5.7 and 20% less than its 5-year quarterly average of 4.4

The revenue fell by 12% YoY

How efficient is Haemonetics business performance

The company's return on invested capital fell by 40% QoQ and by 22% YoY

The company's return on sales fell by 34% QoQ

The company's return on assets fell by 34% QoQ and by 15% YoY

HAE's return on equity is down by 30% since the previous quarter and by 11% year-on-year

What is HAE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HAE.

How did Haemonetics financials performed over time

The total assets is 67% more than the total liabilities

The total liabilities has soared by 82% from the previous quarter and by 60% YoY

The total assets has grown by 44% YoY and by 38% from the previous quarter

The debt is 3.3% smaller than the equity

The debt has soared by 128% since the previous quarter and by 85% year-on-year

The debt to equity has soared by 126% from the previous quarter and by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.